7 research outputs found

    Enzymatic Synthesis Process of EPA- and DHA-Enriched Structured Acylglycerols at the sn-2 Position Starting from Commercial Salmon Oil and Concentrated by Response Surface Methodology under Supercritical Conditions

    No full text
    The bioavailability of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) has shown to be greatly influenced by their location in the triacylglycerol backbone. Therefore, the synthesis of structured acylglycerols (SAcyl), which include eicosapentaenoic acids (EPAs) or docosahexaenoic acids (DHAs) at the sn-2 position, has attracted a great interest. The objective of this study was to optimize the synthesis process of a SAcyl from commercial refined salmon oil and an EPA/DHA concentrate in order to enhance the positioning of EPA and DHA in the sn-2 location of the glycerol moiety. For this purpose, immobilized lipase B from Candida antarctica (nonspecific) was used for the acidolysis process under the CO2 supercritical condition. As a result of carrying out a Draper-Lin composite design through the response surface methodology of 18 experiments, an optimized extraction including SAcyl compounds was obtained. Mass spectrometry (MALDI-TOF) analysis was employed to identify the EPA/DHA location at the sn-2 position in the resulting glycerol moiety. In the fraction obtained, an increase in the EPA and DHA content at the sn-2 position was detected. Remarkably, the optimized SAcyl obtained after 6 h, 82 bar, and 60 °C led to the highest EPA/DHA yield at the sn-2 position in the resulting molecule

    Enzymatic Synthesis Process of EPA- and DHA-Enriched Structured Acylglycerols at the <i>sn</i>-2 Position Starting from Commercial Salmon Oil and Concentrated by Response Surface Methodology under Supercritical Conditions

    No full text
    The bioavailability of n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs) has shown to be greatly influenced by their location in the triacylglycerol backbone. Therefore, the synthesis of structured acylglycerols (SAcyl), which include eicosapentaenoic acids (EPAs) or docosahexaenoic acids (DHAs) at the sn-2 position, has attracted a great interest. The objective of this study was to optimize the synthesis process of a SAcyl from commercial refined salmon oil and an EPA/DHA concentrate in order to enhance the positioning of EPA and DHA in the sn-2 location of the glycerol moiety. For this purpose, immobilized lipase B from Candida antarctica (nonspecific) was used for the acidolysis process under the CO2 supercritical condition. As a result of carrying out a Draper-Lin composite design through the response surface methodology of 18 experiments, an optimized extraction including SAcyl compounds was obtained. Mass spectrometry (MALDI-TOF) analysis was employed to identify the EPA/DHA location at the sn-2 position in the resulting glycerol moiety. In the fraction obtained, an increase in the EPA and DHA content at the sn-2 position was detected. Remarkably, the optimized SAcyl obtained after 6 h, 82 bar, and 60 °C led to the highest EPA/DHA yield at the sn-2 position in the resulting molecule

    Concentration of EPA and DHA from Refined Salmon Oil by Optimizing the Urea–Fatty Acid Adduction Reaction Conditions Using Response Surface Methodology

    Get PDF
    This research focused on obtaining eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) (EPA+DHA) concentrates from refined commercial salmon oil (RCSO). Independent variables of the complexation process were optimized by means of the application of response surface methodology (RSM) in order to obtain the maximum content of such fatty acids (FAs). As a result of employing the optimized conditions for all the variables (6.0, urea:FA content ratio; &#8722;18.0 &#176;C, crystallization temperature; 14.80 h, crystallization time; 500 rpm, stirring speed), high contents of EPA and DHA could be obtained from RCSO, achieving increases of 4.1 and 7.9 times in the concentrate, with values of 31.20 and 49.31 g/100 g total FA, respectively. Furthermore, a 5.8-time increase was observed for the EPA + DHA content, which increased from 13.78 to 80.51 g/100 g total FA. It is concluded that RCSO can be transformed into a profitable source of EPA and DHA (EPA+DHA), thus leading to a product with higher commercial value

    Effect of Structured Phenolic Lipids with EPA/DHA and Gallic Acid against Metabolic-Associated Fatty Liver Disease (MAFLD) in Mice

    No full text
    Obesity is the leading risk factor for developing metabolic (dysfunction)-associated fatty liver disease (MAFLD). The food industry has an essential role in searching for new strategies to improve primary food sources to revert some of the metabolic alterations induced by obesity. There is consistent evidence that long-chain polyunsaturated fatty acids (n-3 LCPUFA) belonging to the n-3 series, i.e., eicosapentaenoic (20:5n-3, EPA) and docosahexaenoic (22:6n-3, DHA) acids, could revert some alterations associated with obesity-induced metabolic diseases. A relevant tool is the synthesis of structured acylglycerols (sAG), which include EPA or DHA at the sn-2 position. On the other hand, it has been reported that a crucial role of antioxidants is the reversion of MAFLD. In this work, we studied the effects of new molecules incorporating gallic acid (GA) into EPA/DHA-rich structured lipids. Mice were fed with a high-fat diet (60%) for three months and were then divided into five groups for supplementation with sAG and sAG structured with gallic acid (structured phenolic acylglycerols, sPAG). sPAG synthesis was optimized using a 2&sup2;-screening factorial design based on the response surface methodology (RSM). Our results show that treatment of sPAG was effective in decreasing visceral fat, fasting glycemia, fasting insulin, suggesting that this new molecule has a potential use in the reversal of MAFLD-associated alterations
    corecore